Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

The candidate treatment outperformed the blockbuster drug that Amgen bought for $13.4 billion.

Bristol Myers Squibb Reports Success in Pivotal Trial of Psoriasis Drug

Bristol Myers Squibb said Phase 3 clinical trial results shows its psoriasis drug candidate outperformed a drug it sold to Amgen last year as part of its Celgene acquisition. BMY stock rose.

Bristol Myers Squibb Says Its Drug Outperforms Drug It Sold To Amgen

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--BMS Announces Deucravacitinib (BMS-986165) Demonstrated Superiority to Placebo and Otezla® in Pivotal Phase 3 Psoriasis Study

Bristol Myers Squibb Announces Deucravacitinib (BMS-986165) Demonstrated Superiority to Placebo and Otezla® (apremilast) in Pivotal Phase 3 Psoriasis Study

CVS Health

Intuitive Surgical

Allscripts Healthcare Solutions

Smith & Nephew

SPDR S&P Pharmaceuticals ETF

Teladoc

These seven healthcare stocks may represent robust long-term investments no matter how reforms in the sector may develop post-election. The post 7 Healthcare Stocks That Can Survive Massive Reform appeared first on InvestorPlace.

7 Healthcare Stocks That Can Survive Massive Reform

NEW YORK, Nov. 2, 2020 /PRNewswire/ -- Lyfebulb, a patient-empowerment platform that connects patients with industry to support user-driven innovation, and Bristol Myers Squibb, a biopharmaceutical company that discovers, develops and delivers innovative medicines to help patients prevail...

Lyfebulb and Bristol Myers Squibb Partner to Address Unmet Needs in Multiple Sclerosis through Patient-Driven Innovation

Amgen

Amgen and Bristol Myers Squibb have both drawn heavy criticism for their pricing practices.

Is Drug Pricing Backlash a Serious Risk for Big Pharma Stocks?

Investors will focus on regular top and bottom-line numbers along with key pipeline updates when Bristol-Myers (BMY) reports third-quarter 2020 results.

Is a Beat in the Cards for Bristol-Myers' (BMY) Q3 Earnings?

MyoKardia

MYOK may have seemed an expensive and unwanted use of cash at first, but it couldn't have been too bad for management to have bought it. Indeed, successfully raising clinical awareness for HCM and R&D successes will have made the acquisition a good bargain.

Bristol Myers Squibb: The MyoKardia Acquisition Was Not A Bad Idea

AbbVie

bluebird bio

Mustang Bio

Regeneron Pharmaceuticals

Vertex Pharmaceuticals

Biotech stocks are always going to be here, in good times and bad. Let's look at a few that are worth considering on the long side.

7 Cutting-Edge Biotech Stocks for Tomorrow 

SAN FRANCISCO--(BUSINESS WIRE)--insitro, a machine-learning driven drug discovery and development company, today announced that it has entered into a five-year, discovery collaboration with Bristol Myers Squibb (NYSE: BMY) focused on the discovery and development of novel therapies for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). “Neurodegenerative disorders like ALS and FTD have historically been a challenging therapeutic area, with no disease modifyi

insitro Announces Five-Year Discovery Collaboration with Bristol Myers Squibb to Discover and Develop Novel Treatments for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia

A reader asked me a question about the sizing of BMY.RT. I think it is an interesting subject and wanted to share an expanded version of my answer.

Bristol-Myers Contingent Value Right Shares: Position Sizing Of Securities With Binary Outcomes

Merck

These drugmakers are proof that reinvesting in pipeline projects pays off in the long run.

These 2 Pharmas Have Made Their Pipelines a Competitive Advantage

In the latest trading session, Bristol Myers Squibb (BMY) closed at $59.67, marking a -0.77% move from the previous day.

Bristol Myers Squibb (BMY) Stock Moves -0.77%: What You Should Know

Apple

Home Depot

Microsoft

Walmart

Given strong dividend growth and big money signals, these stocks could be worth a spot in a yield-oriented portfolio.

Best Dividend Stocks for November 2020

PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)---- $BMY #AFib--BMS–Pfizer Alliance, with the support of leading advocacy organizations and medical societies, announce the launch of the No Time to Wait campaign.

Decreases in Americans' Primary Care Visits May Lead to Late Diagnoses of Potentially Serious Conditions1

Mastercard

Sometimes, buying bigger can really be better.

Got $3,000? 4 Proven Stocks to Buy Right Now

Despite almost a 32% rise in Bristol Myers Squibb's stock since the March lows of this year, at the current price of around $60 per share, we believe BMY stock has a significant upside. Why is that?

Bristol Myers Squibb Stock Looks Attractive At $60

On Oct. 19, I reviewed three of the 10 companies a Jeffries health care analyst thinks are most likely to be acquired by members of Big Pharma. Now let's look at numbers four through six on the list Jeffries' Jaret Holtz provided to FierceBiotech.

Bristol-Myers' Acquisition of Bluebird Seems to Make Sense

An analyst at Guggenheim Securities turned bullish on pharma giant Bristol-Myers Squibb Co (NYSE: BMY) Monday, basing their optimism on a revival in sales of its flagship immuno-oncology drug Opdivo. The Bristol-Myers Squibb Analyst:  Analyst Seamus Fernandez upgraded Bristol-Myers Squibb shares from Neutral to Buy with a new $70 price target.

Bristol-Myers Squibb Analyst Sees Multiple Expansion Story, Limited Near-Term Downside Risk

GlaxoSmithKline

Seagen

Let us take a look at some drug/biotech stocks including Glaxo (GSK) and Merck (MRK) that are poised to beat on earnings for the third quarter.

5 Big Pharma/Biotech Stocks Set to Trump Q3 Earnings Estimates

The CHMP passes a favorable opinion for the approval of Bristol-Myers' (BMY) Opdivo to address advanced/ metastatic esophageal squamous cell carcinoma in the EU.

Bristol-Myers' (BMY) Opdivo Gets Positive CHMP View for ESCC

Exelixis

Bristol Myers Squibb and Exelixis announced Monday that the FDA had granted priority review for their combined treatment for a form of advanced kidney cancer; and BMY stock, EXEL stock rose. The post Bristol Myers Squibb, Exelixis Granted FDA Priority Review For Kidney Cancer Treatment appeared first on Investor's Business Daily.

Bristol Myers Squibb, Exelixis Granted FDA Priority Review For Kidney Cancer Treatment

PRINCETON, N.J. & ALAMEDA, Calif.--(BUSINESS WIRE)---- $BMY #BMS--US FDA Accepts for Priority Review Applications for OPDIVO® in Combination with CABOMETYX® in Advanced Renal Cell Carcinoma

U.S. Food and Drug Administration Accepts for Priority Review Applications for OPDIVO® (nivolumab) in Combination with CABOMETYX® (cabozantinib) in Advanced Renal Cell Carcinoma

Freshpet

Alphabet

NextEra Energy

Stock market crashes and corrections are inevitable -- but they do open the door to some incredible bargains for investors.

4 Perfect Stocks to Buy if the Stock Market Crashes

Here's how these two big drugmakers stack up against each other in several key categories.

News for Bristol-Myers Stock (BMY)